Editas Medicine (EDIT) Cash & Equivalents (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Cash & Equivalents data on file, last reported at $146.6 million in Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 11.48% year-over-year to $146.6 million in Q4 2025; TTM through Dec 2025 was $146.6 million, a 11.48% increase from a year earlier, with the FY2025 full-year figure at $146.6 million, up 11.48% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $146.6 million, down from $165.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for EDIT reached as high as $354.9 million in Q1 2021 and fell as low as $64.4 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $169.8 million across 5 years, with a median of $144.1 million in 2022.
• Across the five-year window, Cash & Equivalents sank 70.82% in 2024 and surged 114.99% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $203.5 million in 2021, then slumped by 30.46% to $141.5 million in 2022, then dropped by 12.63% to $123.7 million in 2023, then advanced by 6.38% to $131.5 million in 2024, then advanced by 11.48% to $146.6 million in 2025.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $146.6 million in Q4 2025, $165.6 million in Q3 2025, and $138.5 million in Q2 2025.